Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 294

1.

CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.

Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN.

Clin Cancer Res. 2005 Jan 1;11(1):370-9.

2.

Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice.

Mauch C, Grimm C, Meckel S, Wands JR, Blum HE, Roggendorf M, Geissler M.

Vaccine. 2001 Oct 12;20(1-2):170-80.

PMID:
11567762
3.

Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.

Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA.

Clin Cancer Res. 2004 Feb 1;10(3):1047-56.

4.
5.

Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.

Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE.

J Immunol. 2002 Apr 15;168(8):3983-91.

6.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

8.

Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.

Briones J, Timmerman JM, Panicalli DL, Levy R.

J Natl Cancer Inst. 2003 Apr 2;95(7):548-55.

PMID:
12671023
9.

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Jensen M, Tan G, Forman S, Wu AM, Raubitschek A.

Biol Blood Marrow Transplant. 1998;4(2):75-83.

PMID:
9763110
10.

Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.

Funakoshi S, Longo DL, Murphy WJ.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):93-101.

PMID:
8732692
11.

Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.

Rosato A, Zoso A, Milan G, Macino B, Dalla Santa S, Tosello V, Di Carlo E, Musiani P, Whalen RG, Zanovello P.

J Immunol. 2003 Nov 15;171(10):5172-9.

12.

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.

Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.

Clin Cancer Res. 2005 Aug 1;11(15):5566-71.

13.

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.

Sapra P, Allen TM.

Clin Cancer Res. 2004 Apr 1;10(7):2530-7. Erratum in: Clin Cancer Res. 2004 Jul 15;10(14);4893.

14.

Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.

Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE.

J Immunother. 2009 Apr;32(3):207-18. doi: 10.1097/CJI.0b013e318194a921.

PMID:
19242379
15.

A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.

Pinchuk I, Starcher BC, Livingston B, Tvninnereim A, Wu S, Appella E, Sidney J, Sette A, Wizel B.

J Immunol. 2005 May 1;174(9):5729-39.

16.

Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice.

Grujic M, Holst PJ, Christensen JP, Thomsen AR.

J Gen Virol. 2009 Feb;90(Pt 2):414-22. doi: 10.1099/vir.0.002105-0.

PMID:
19141451
17.

DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells.

Miyazaki M, Nakatsura T, Yokomine K, Senju S, Monji M, Hosaka S, Komori H, Yoshitake Y, Motomura Y, Minohara M, Kubo T, Ishihara K, Hatayama T, Ogawa M, Nishimura Y.

Cancer Sci. 2005 Oct;96(10):695-705.

19.

Induction of murine ras oncogene peptide-specific T cell responses by immunization with plasmid DNA-based minigene vectors.

Lindinger P, Mostböck S, Hammerl P, Hartl A, Thalhamer J, Abrams SI.

Vaccine. 2003 Oct 1;21(27-30):4285-96.

PMID:
14505911
20.

Supplemental Content

Support Center